Open Access<p>Lower Serum Matrix Metalloproteinase‑9 in Metastatic Patients with Esophageal Squamous Cell Carcinoma After Concurrent Radiotherapy Was Significant for Prognosis</p>
Author(s) -
Ziqi Ye,
Hongying Zhao,
Wuyuan Zhou,
Ye Tao,
Changran Geng,
Xiaofeng Li,
Yuan Liu,
Mengnan Du,
Heng Xu,
Qiang Wang
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s280791
Subject(s) - medicine , chemotherapy , radiation therapy , esophageal squamous cell carcinoma , oncology , gastroenterology , matrix metalloproteinase , biomarker , metastasis , matrix metalloproteinase 9 , carcinoma , cancer , biochemistry , chemistry
This study was designed to investigate the relationships of serum matrix metalloproteinase 9 (MMP-9) level and treatment response in esophageal squamous cell carcinoma (ESCC) patients treated with chemotherapy or concurrent radiotherapy.